Alexion Pharmaceuticals, Inc. (ALXN) Shares Sold by BlackRock Inc.

BlackRock Inc. lowered its holdings in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 7.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 18,004,610 shares of the biopharmaceutical company’s stock after selling 1,352,721 shares during the period. BlackRock Inc. owned about 8.06% of Alexion Pharmaceuticals worth $2,153,171,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in ALXN. Jennison Associates LLC lifted its position in shares of Alexion Pharmaceuticals by 720.0% in the 3rd quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock worth $748,116,000 after purchasing an additional 4,682,336 shares during the period. Assenagon Asset Management S.A. lifted its position in Alexion Pharmaceuticals by 4,509.0% during the 3rd quarter. Assenagon Asset Management S.A. now owns 884,150 shares of the biopharmaceutical company’s stock valued at $124,037,000 after acquiring an additional 864,967 shares during the period. Alkeon Capital Management LLC purchased a new position in Alexion Pharmaceuticals during the 3rd quarter valued at about $70,145,000. Wells Fargo & Company MN lifted its position in Alexion Pharmaceuticals by 32.7% during the 3rd quarter. Wells Fargo & Company MN now owns 1,558,531 shares of the biopharmaceutical company’s stock valued at $218,647,000 after acquiring an additional 383,713 shares during the period. Finally, Pictet Asset Management Ltd. lifted its position in Alexion Pharmaceuticals by 46.7% during the 3rd quarter. Pictet Asset Management Ltd. now owns 1,126,275 shares of the biopharmaceutical company’s stock valued at $158,005,000 after acquiring an additional 358,695 shares during the period. 95.38% of the stock is currently owned by institutional investors.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) traded up $4.34 during mid-day trading on Friday, hitting $118.93. 1,595,891 shares of the stock traded hands, compared to its average volume of 2,140,000. Alexion Pharmaceuticals, Inc. has a 1 year low of $96.18 and a 1 year high of $149.34. The stock has a market capitalization of $26,360.00, a P/E ratio of 54.81, a PEG ratio of 1.10 and a beta of 1.16. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.10 and a quick ratio of 2.62.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.09 by $0.39. Alexion Pharmaceuticals had a net margin of 12.48% and a return on equity of 12.94%. The company had revenue of $909.70 million for the quarter, compared to analysts’ expectations of $880.38 million. During the same quarter in the previous year, the business posted $1.26 earnings per share. Alexion Pharmaceuticals’s quarterly revenue was up 9.5% on a year-over-year basis. equities analysts expect that Alexion Pharmaceuticals, Inc. will post 6.12 EPS for the current fiscal year.

A number of research analysts recently issued reports on the stock. Deutsche Bank set a $161.00 price target on shares of Alexion Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, February 9th. BMO Capital Markets raised their price objective on shares of Alexion Pharmaceuticals from $177.00 to $180.00 and gave the company an “outperform” rating in a research note on Friday, February 9th. Stifel Nicolaus restated a “buy” rating and set a $151.00 price objective on shares of Alexion Pharmaceuticals in a research note on Friday, February 9th. Citigroup reduced their price target on shares of Alexion Pharmaceuticals from $173.00 to $170.00 and set a “buy” rating for the company in a research note on Friday, February 9th. Finally, Morgan Stanley lifted their price target on shares of Alexion Pharmaceuticals from $148.00 to $151.00 and gave the stock an “overweight” rating in a research note on Friday, February 9th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and twenty-one have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $152.77.

In other Alexion Pharmaceuticals news, SVP Heidi L. Wagner sold 655 shares of the business’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $117.26, for a total transaction of $76,805.30. Following the transaction, the senior vice president now owns 32,635 shares in the company, valued at $3,826,780.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Heidi L. Wagner sold 1,774 shares of the business’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $116.31, for a total transaction of $206,333.94. Following the transaction, the senior vice president now owns 47,212 shares in the company, valued at approximately $5,491,227.72. The disclosure for this sale can be found here. Insiders have sold 28,930 shares of company stock worth $3,378,199 in the last quarter. Company insiders own 4.35% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/25/alexion-pharmaceuticals-inc-alxn-holdings-reduced-by-blackrock-inc.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply